Diabetes Therapies & Diagnostics: Global Markets

Table of Contents

• Diabetes Therapies & Diagnostics: Global Markets
• Chapter 1 - SUMMARY
  • SUMMARY TABLE: GLOBAL DIABETES MARKET FORECAST BY SEGMENT, THROUGH 2013 ($ BILLIONS)
  • SUMMARY FIGURE: GLOBAL DIABETES MARKET FORECAST BY SEGMENT, 2006-2013 ($ BILLIONS)
• Chapter 2 - OVERVIEW
  • OVERVIEW
  • TABLE 1 PREVALENCE OF TYPE I AND II DIABETES: TOP SIX COUNTRIES WITH HIGH GROWTH PROJECTIONS, THROUGH 2013 (MILLIONS)
  • TABLE 2 PREVALENCE OF TYPE II DIABETES: TOP SIX COUNTRIES WITH PROJECTIONS, THROUGH 2013 (MILLIONS)
  • TABLE 3 DEFINITIONS OF THE FOUR TYPES OF DIABETES
  • TABLE 3 (CONTINUED)
  • TABLE 4 SUMMARY OF DIABETES PRODUCTS AND APPLICATIONS
• Chapter 3 - DIABETES DISEASE
  • CAUSATION, RISK FACTORS, AND COMPLICATIONS
  • TABLE 5 CAUSAL OR RISK FACTORS BY DIABETES TYPE
  • TABLE 6 COMPLICATIONS BY TYPE OF DIABETES
    • DIABETES MANAGEMENT
      • DIABETES MANAGEMENT (CONTINUED)
      • DIABETES MANAGEMENT (CONTINUED)
• Chapter 4 - DIABETES PRODUCT SEGMENTS
  • CONTINUOUS GLUCOSE MONITORING SYSTEMS (CGMS)
  • CONTINUOUS GLUCOSE MONITORING ý (CONTINUED)
  • TABLE 7 FDA APPROVED CONTINUOUS GLUCOSE MONITORING SYSTEMS BY MANUFACTURER
    • INSULIN INFUSION PUMPS
  • TABLE 8 FDA APPROVED INSULIN INFUSION PUMPS BY MANUFACTURER
  • TABLE 9 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION PUMPS, THROUGH 2013 ($ MILLIONS)
  • FIGURE 1 PROJECTED MARKET LEADER SALES OF CONTINUOUS GLUCOSE MONITORING SYSTEMS AND INSULIN INFUSION PUMPS, 2006-2013 ($ MILLIONS)
    • INSULIN-DEPENDENT DRUGS
  • TABLE 10 TECHNOLOGICAL EVOLUTION OF INSULIN DELIVERY METHODS
  • TABLE 11 FDA APPROVED INSULIN-DEPENDENT PRODUCTS BY MARKET LEADER
    • INSULIN-DEPENDENT DRUGS (CONTINUED)
  • TABLE 12 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER, THROUGH 2013 ($ MILLIONS)
  • FIGURE 2 INSULIN-DEPENDENT DRUG SALES FORECAST BY MANUFACTURER, 2006-2013 ($ MILLIONS)
    • INSULIN-INDEPENDENT DRUGS
  • TABLE 13 THE SEVEN CLASSES OF TYPE II DIABETES DRUGS
  • TABLE 13 (CONTINUED)
• SULFONYLUREAS
  • TABLE 14 FDA APPROVED BRAND-NAME SULFONYLUREA DRUGS BY DRUGMAKER
  • TABLE 14 (CONTINUED)
• BIGUANIDES
  • TABLE 15 FDA APPROVED BRAND-NAME BIGUANIDE DRUGS
• ALPHA-GLUCOSIDASE INHIBITORS
  • TABLE 16 FDA APPROVED BRAND-NAME ALPHA-GLUCOSIDASE INHIBITOR DRUGS
    • MEGLITINIDES
  • TABLE 17 FDA APPROVED BRAND-NAME MEGLITINIDE DRUGS
• THIAZOLIDINEDIONES (TZD)
  • TABLE 18 FDA APPROVED BRAND-NAME THIAZOLIDINEDIONES DRUGS
• INCRETIN MIMETICS
  • TABLE 19 FDA APPROVED BRAND-NAME INCRETIN MIMETICS DRUGS
    • DIPEPTIDYL PEPTIDASE 4 (DPP-4)
  • TABLE 20 FDA APPROVED BRAND-NAME DPP-4 DRUGS
  • TABLE 21 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST, THROUGH 2013 ($ MILLIONS)
  • FIGURE 3 TOP SELLING BRAND-NAME INSULIN-INDEPENDENT DRUG FORECAST, 2006-2013 ($ MILLIONS)
    • SURGICAL TREATMENT OF DIABETES
  • TABLE 22 THE MARKET FOR NEW CLASSES OF DIABETES TREATMENTS
• Chapter 5 - DIABETIC COMPLICATIONS MARKET
  • RETINOPATHY (EYE DISEASE)
  • NEUROPATHY (NERVE DISEASE)
  • NEPHROPATHY (KIDNEY DISEASE)
  • ARTERIOSCLEROSIS (CARDIOVASCULAR DISEASE)
  • OTHER COMPLICATIONS
  • PRESCRIPTION DRUGS FOR DIABETES COMPLICATIONS
    • CHOLESTEROL DRUGS
      • Torcetrapib (Pfizer)
    • HYPERTENSION DRUGS
      • Exforge (Novartis)
      • Tekturna (Novartis)
    • CORONARY INTERVENTION
      • Effient (Eli Lilly/Daiichi Sankyo)
  • TABLE 23 DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS, BY MANUFACTURER
  • TABLE 24 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, THROUGH 2013 ($ MILLIONS)
  • FIGURE 4 FORECAST OF TOP SELLING DRUGS USED IN THE TREATMENT OF COMMON DIABETIC COMPLICATIONS BY MANUFACTURER, 2006-2013 ($ MILLIONS)
• Chapter 6 - GENERIC ANTIDIABETIC DRUG MARKET
  • GENERIC ANTIDIABETIC DRUG MARKET
  • TABLE 25 FDA APPROVED GENERIC SULFONYLUREAS BY MANUFACTURER
  • TABLE 25 (CONTINUED)
  • TABLE 26 FDA APPROVED GENERIC BIGUANIDES BY MANUFACTURER
  • TABLE 27 FDA APPROVED GENERIC MEGLITINIDES BY MANUFACTURER
  • TABLE 28 FDA APPROVED GENERIC THIAZOLIDINEDIONES, BY MANUFACTURER
  • TABLE 29 TOP SELLING GENERIC ANTIDIABETIC DRUG FORECAST, THROUGH 2013 ($ MILLIONS)
• Chapter 7 - DIABETES DRUGS IN DEVELOPMENT
  • CLINICAL TRIALS PHASES I-IV
    • PHASE I CLINICAL TRIALS ON DIABETES DRUGS
  • TABLE 30 DIABETES DRUGS IN PHASE I CLINICAL TRIALS
    • PHASE II CLINICAL TRIALS ON DIABETES DRUGS
  • TABLE 31 DIABETES DRUGS IN PHASE II CLINICAL TRIALS
    • PHASE III CLINICAL TRIALS ON DIABETES DRUGS
  • TABLE 32 DIABETES DRUGS IN PHASE III CLINICAL TRIALS
    • PHASE IV CLINICAL TRIALS ON DIABETES DRUGS
  • TABLE 33 DIABETES DRUGS IN PHASE IV CLINICAL TRIALS
    • COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS
  • TABLE 34 COMPLETED CLINICAL TRIALS ON TYPE I DIABETES DRUGS
    • COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS
  • TABLE 35 COMPLETED CLINICAL TRIALS ON TYPE II DIABETES DRUGS
    • COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPES OF DIABETES
  • TABLE 36 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT BOTH TYPE I AND TYPE II DIABETES
    • PHASE I CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
  • TABLE 37 PHASE I CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
    • PHASE II CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
  • TABLE 38 PHASE II CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
    • PHASE III CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
  • TABLE 39 PHASE III CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
    • PHASE IV CLINICAL TRIALS ON TREATMENTS FOR DIABETES COMPLICATIONS
  • TABLE 40 PHASE IV CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
  • COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
  • TABLE 41 COMPLETED CLINICAL TRIALS ON DRUGS USED TO TREAT COMMON DIABETIC COMPLICATIONS
    • INCRETIN MIMETICS
    • PRAMLINTIDE
    • EXENATIDE
    • LIRAGLUTIDE (PHASE III)
  • DPP-4 INHIBITORS
    • VILDAGLIPTIN
    • SITAGLIPTIN
  • GLITAZARS (DUAL-PPAR AGONISTS)
    • MURAGLITAZAR
• Chapter 8 - PATENT ANALYSIS OF DIAGNOSTIC AND THERAPEUTIC DIABETES TREATMENTS
  • TABLE 42 WORLDWIDE SHARES OF PATENTS AND PUBLISHED PATENT APPLICATIONS ON TYPE I AND TYPE II DIABETES TREATMENTS BY SELECTED COUNTRY, 1/1/2001-11/1/2007 (NUMBER)
• U.S. AND EUROPEAN PATENTS ON TYPE I DIABETES TREATMENTS
  • TABLE 43 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE I DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
• U.S. AND EUROPEAN PATENTS ON TYPE II DIABETES TREATMENTS
  • TABLE 44 U.S. AND EUROPEAN SHARES OF PATENTS ON TYPE II DIABETES TREATMENTS BY PATENT HOLDER, 1/1/1991 TO 11/30/2007 (NUMBER)
  • TABLE 45 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
  • TABLE 46 U.S. AND EUROPEAN SHARES OF PATENTS ON INCRETIN MIMETICS AND DPP-4 INHIBITORS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
  • TABLE 47 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SITAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
  • TABLE 48 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON VILDAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
  • TABLE 49 U.S. PATENT SHARES OF VILDAGLIPTIN BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
  • TABLE 50 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON SAXAGLIPTIN BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
  • TABLE 51 U.S. PATENT SHARES OF LIRAGLUTIDE BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
  • TABLE 52 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON TESAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
  • TABLE 53 WORLDWIDE SHARES OF PATENTS AND PATENT APPLICATIONS ON MURAGLITAZAR BY PATENT HOLDER, 1/1/2001-11/1/2007 (NUMBER)
• U.S. AND EUROPEAN PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS
  • TABLE 54 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN DELIVERY OTHER THAN SUBCUTANEOUS METHODS, 1/1/1991-11/30/2007 (NUMBER)
• U.S. AND EUROPEAN PATENTS ON INSULIN INFUSION PUMPS
  • TABLE 55 U.S. AND EUROPEAN SHARES OF PATENTS ON INSULIN INFUSION PUMPS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
• U.S. AND EUROPEAN PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS
  • TABLE 56 U.S. AND EUROPEAN SHARES OF PATENTS ON CONTINUOUS GLUCOSE MONITORING SYSTEMS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
  • TABLE 57 U.S. AND EUROPEAN SHARES OF PATENTS ON BLOOD GLUCOSE METERS BY PATENT HOLDER, 1/1/1991-11/30/2007 (NUMBER)
• Chapter 9 - INSULIN INHALER MARKET
  • DRUGMAKERS DEVELOPING INHALABLE INSULIN
• PFIZER
  • ABBOTT LABORATORIES AND KOS PHARMACEUTICALS
  • ELI LILLY & CO. AND ALKERMES
  • MANNKIND CORP.
  • NOVO NORDISK AND ARADIGM
  • BAXTER INTERNATIONAL
  • NASTECH PHARMACEUTICAL CO.
  • GENEREX BIOTECHNOLOGY
  • TABLE 58 INHALED INSULIN PRODUCTS UNDER DEVELOPMENT BY COMPANY
• Chapter 10 - INSULIN INFUSION PUMP MARKET
  • INSULIN INFUSION PUMP MARKET
    • INSULIN INFUSION PUMP MARKET (CONTINUED)
    • INSULIN INFUSION PUMP MARKET (CONTINUED)
    • INSULIN INFUSION PUMP MARKET (CONTINUED)
• Chapter 11 - INSULIN DISPENSING PATCH MARKET
  • INSULIN DISPENSING PATCH MARKET
  • TABLE 59 INSULIN DISPENSING PATCHES BY MANUFACTURER
• Chapter 12 - COMPANY PROFILES
  • ABBOTT LABORATORIES, INC.
    • ABBOTT DIABETES CARE, INC.
  • ACTAVIS
    • ACTAVIS U.S.
  • ALIZYME, PLC
  • ALKERMES INC.
    • ALKERMES INC. (CONTINUED)
  • AMYLIN PHARMACEUTCIALS, INC.
  • ARADIGM CORP.
  • ASTELLA PHARMACEUTICALS
  • ASTRAZENECA, PLC
    • ASTRAZENECA U.S.
      • AstraZeneca U.S. (Continued)
  • BARR PHARMACEUTICALS, INC.
    • BARR PHARMACEUTICALS, INC. (CONTINUED)
  • BAYER SCHERING PHARMA AG
    • BAYER HEALTHCARE PHARMACEUTICALS U.S.
    • BAYER GLOBAL HEALTHCARE DIABETES CARE
      • Bayer Global HealthCare Diabetes Care (Continued)
      • Bayer Global HealthCare Diabetes Care (Continued)
  • BRISTOL-MYERS SQUIBB CO.
    • BRISTOL-MYERS SQUIBB CO. (CONTINUED)
  • CARACO PHARMA LABS, LTD.
    • DAIICHI-SANKYO, LTD.
  • DAIICHI-SANKYO, INC.
    • Daiichi-Sankyo, Inc. (Continued)
  • DEBIOTECH
  • DEPOMED, INC.
    • DEPOMED, INC. (CONTINUED)
  • DEXCOM
  • DR. REDDY' S LABORATORIES, LTD.
    • DR. REDDY' S LABORATORIES, LTD.
  • ELI LILLY & CO.
    • ELI LILLY & CO. (CONTINUED)
    • ELI LILLY & CO. (CONTINUED)
    • ELI LILLY & CO. (CONTINUED)
  • GLAXOSMITHKLINE, PLC
    • GLAXOSMITHKLINE
  • INSULET CORP.
  • JOHNSON & JOHNSON CO.
    • LIFESCAN, INC.
  • KERYX BIOPHARMACEUTICALS INC.
  • MANNKIND CORP.
    • MANNKIND CORP. (CONTINUED)
  • MEDTRONIC INC.
    • MEDTRONIC DIABETES
      • Medtronic Diabetes (Continued)
  • MERCK & CO., INC.
    • MERCK & CO., INC. (CONTINUED)
  • MYLAN, INC.
  • NOVARTIS AG
    • NOVARTIS U.S.
      • Novartis U.S. (Continued)
  • NOVO NORDISK A/S
  • NOVO NORDISK U.S.
    • Novo Nordisk U.S. (Continued)
  • PAR PHARMACEUTICAL COMPANIES, INC.
  • PFIZER, INC.
  • RANBAXY LABORATORIES, INC.
    • RANBAXY U.S.
  • ROCHE DIAGNOSTICS CORP.
  • SANDOZ (NOVARTIS GENERIC DIVISION)
    • SANDOZ U.S.
  • SANOFI-AVENTIS A.G.
    • SANOFI-AVENTIS U.S., LLC
      • Sanofi-Aventis U.S., LLC (Continued)
  • SANTHERA PHARMACEUTICALS
  • SMITHS MEDICAL
    • SMITHS MEDICAL ASD, INC.
  • TAKEDA PHARMACEUTICAL CO., LTD.
  • TEVA PHARMACEUTICALS, INC.
    • TEVA PHARMACEUTICALS USA
  • WATSON LABORATORIES, INC.
  • WYETH
    • WYETH (CONTINUED)